Keystone Symposia

Clarion Hotel Sign Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2013

Here are the related meetings in 2020:
Beyond a Million Genomes: From Discovery to Precision Health (A4)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Human Genomics and Personalized Medicine (E3)

Organizer(s) Kelly A. Frazer and Geoffrey S. Ginsburg
June 17—21, 2013
Clarion Hotel Sign • Stockholm, Sweden
Abstract Deadline: Feb 20, 2013
Late Abstract Deadline: Mar 19, 2013
Scholarship Deadline: Feb 20, 2013
Early Registration Deadline: Apr 16, 2013

Organized in collaboration with Knut and Alice Wallenberg Foundation and Science for Life Laboratory - Stockholm. Sponsored by AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., H3 Biomedicine Inc., Nestlé Institute of Health Sciences and Onyx Pharmaceuticals, Inc.

Summary of Meeting:
The last decade has seen considerable progress in our understanding of genomics and the era of personalized medicine is just around the corner. Importantly, emerging data on the structure and function of the human genome are providing insights into the molecular basis of inherited disease and providing opportunities to improve human health through new approaches to diagnostics and therapy. These advances will impact all aspects of human health, ranging from cancer to other chronic diseases. Making genomic medicine a reality requires novel collaborations between basic scientists, translational scientist, regulatory bodies and health insurance bodies. Therefore, the Keystone Symposia meeting on Human Genomics and Personalized Medicine is a timely opportunity to bring leading researchers together to discuss the critical issues facing this emerging field. The meeting will focus on various aspects of the field, including genomics and the transition to genomic medicine (clinical care based on genomic information), the analysis of complex data sets, the development of robust bio-repositories, public access to large data sets being generated from funds from NIH and other agencies, and key regulatory issues and public policy. Importantly, the meeting will help establish communication and interactions enabling a faster implementation of genomic medicine and will also benefit from its international participation by highlighting areas of research that are of global concern.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


Arrival and Registration

Coffee & Snacks Available

Welcome and Keynote Address

B 1-2
* Geoffrey S. Ginsburg, Duke University, USA
Welcome Remarks

John Bell, University of Oxford, UK
Bringing Genomics to the Bedside

Breakthroughs in Genomic and Personalized Medicine

B 1-2
* Kelly A. Frazer, University of California San Diego School of Medicine, USA

Peter Mueller, Mueller Health Foundation, USA
Kalydeco: Targeting the G551D Mutation in CF

Geoffrey S. Ginsburg, Duke University, USA
Novel Host-Based Approaches to the Diagnosis of Infectious Disease

Stephen F. Kingsmore, Rady Children's Institute for Genomic Medicine, USA
Pediatric Genomic Medicine



Individual Hotel
Poster Setup

Poster Viewing

Genomes and Biology

B 1-2
* Thomas J. Hudson, AbbVie, USA

Mathias Uhlen, KTH Royal Inst of Technology, Sweden
Defining the Human Tissue-Specific Proteome based on Transcriptomics and Antibody-Based Protein Profiling

Kelly A. Frazer, University of California San Diego School of Medicine, USA
Genomic Approaches to Understanding Cancer Progression

Martin J. Blaser, New York University School of Medicine, USA
Perturbing the Early Life Microbiome and its Consequences

Andrew P. Feinberg, Johns Hopkins University School of Medicine, USA
The Epigenetic Basis of Common Human Disease

Lili Milani, University of Tartu, Estonia
Short Talk: Genome-Wide DNA Methylation and Gene Expression Changes in Whole Blood, CD4+ and CD8+ T-Cells during Healthy Aging

Coffee Break


Poster Session 1

Coffee Available

Cancer Genomics and Applications

B 1-2
* Andrew P. Feinberg, Johns Hopkins University School of Medicine, USA

Paul S. Mischel, University of California, San Diego, USA
The Cancer Genome Atlas and the Future of Cancer Diagnosis and Treatment

Thomas J. Hudson, AbbVie, USA
Linking Cancer Treatment Decisions with Large-Scale Mutation Surveys

Jessica Nordlund, Uppsala University, Sweden
Short Talk: The DNA Methylation Landscape of Pediatric Acute Lymphoblastic Leukemia

Steven Shak, Genomic Health Inc., USA
Translating Genomics into Clinical Practice: Lessons from Oncotype DX

Hiroyuki Mano, University of Tokyo, Japan
Targeting Essential Growth Drivers in Human Cancer

On Own for Dinner



Individual Hotel
Advances and Challenges in the Field

B 1-2
* Kelly A. Frazer, University of California San Diego School of Medicine, USA

Janet Woodcock, US Food and Drug Administration, USA
A Regulatory Pathway to Personalized Medicine

Dan M. Roden, Vanderbilt University Medical Center, USA
Integration and Implementation of Genetic Information into Health Systems

Jill P. Mesirov, Broad Institute, USA
Computational Approaches for Genomic Medicine

Howard J. Jacob, HudsonAlpha Institute for Bioltechnology, USA
Advances in Clinical Sequencing

X. Sunney Xie, Peking University, China
Short Talk: Single-Cell Genomics: Life at the Single Molecule Level

Coffee Break

Poster Setup


Poster Viewing


B 1-2
* Dan M. Roden, Vanderbilt University Medical Center, USA

Alan R. Shuldiner, Regeneron Pharmaceuticals, Inc, USA
Genomic Management of Anti-Platelet Therapeutics

Y.T. Chen, Duke University, USA
Realizing the Promise of Personalized Medicine: HLA-B*1502 Screen in Preventing Carbamazepine-Induced Toxic Effects

Keith J. Johnson, Novartis Institutes for BioMedical Research, Inc., USA
Pharmacogenetic Applications to Enable Drug Development for General Medicine Indications

Federico Innocenti, University of North Carolina at Chapel Hill, USA
Pharmacogenetics of Cancer Therapeutics: Focus on the Germline Genome

Shannon Gibson, University of Toronto, Canada
Short Talk: Ethical, Legal and Social Issues in Pharmacogenomics: A Qualitative Study of the Perspectives of Canadian Stakeholders

Coffee Available

Personalized Genomes

B 1-2
* Howard J. Jacob, HudsonAlpha Institute for Bioltechnology, USA

Michael P. Snyder, Stanford University School of Medicine, USA
Adventures in Personal Genomics: iPOP of Healthy and Disease States

William A. Gahl, NHGRI, National Institutes of Health, USA
Whole Exome Sequencing for Undiagnosed Diseases

Alan H. Bryce, Mayo Clinic, USA
Short Talk: A Pilot Study of Whole Genome, Whole Exome and RNA Sequencing with CLIA Validation to Identify Potential Therapeutic Targets in Advanced Cancer Patients

George M. Church, Harvard Medical School, USA
The Personal Genome Project and the Future of Medicine

Social Hour with Lite Bites

Poster Session 2




Individual Hotel

B 1-2
* Janet Woodcock, US Food and Drug Administration, USA

Susanne B. Haga, Duke University, USA
Introducing Genomics in the Clinic: Development of New Delivery Systems

Laura Lyman Rodriguez, NHGRI, National Institutes of Health, USA
Bringing Genomics into Medicine: Advancing the Policy Agenda

Andelka M. Phillips, University of Oxford, UK
Short Talk: We Agree to Sequence your Genomic Data, and you Agree to X, Y, Z…

Katherine Payne, University of Manchester, UK
Quantifying the Economic Value of Personalized Medicine

Jane Kaye, University of Oxford, UK
Privacy, Data-Sharing Frameworks, Global Governance and Translational Research

Coffee Break

On Own for Lunch and Recreation

Coffee Available

Translating Biomarkers to Personalized Medicine

B 1-2
* Geoffrey S. Ginsburg, Duke University, USA

Michelle Penny, Biogen, USA
Integration of Genomic Technologies into Drug Discovery and Development

Johan Lundin, University of Helsinki, Finland
Developing Diagnostics from Biomarkers

Thomas Metcalfe, Oncotest GmbH - Institute for Experimental Oncology, Germany
Co-Development of Therapeutics and Companion Diagnostics

Social Hour with Lite Bites


B 1-3



*Session Chair †Invited, not yet responded.

Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

AstraZeneca Boehringer Ingelheim Pharmaceuticals, Inc.
H3 Biomedicine Inc. Nestlé Institute of Health Sciences
Onyx Pharmaceuticals, Inc. Science for Life Laboratory - Stockholm
Knut and Alice Wallenberg Foundation

We gratefully acknowledge additional support for this conference from:

Science Translational Medicine

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Institutes for BioMedical Research

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

S. Karger AG - ISCN 2013

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179